Vaptans and the Treatment of Water-Retaining Disorders

Gross, 1987, Pathogenesis of clinical hyponatremia, Eur J Clin Invest, 17, 123, 10.1111/j.1365-2362.1987.tb02391.x Hoorn, 2006, Development of severe hyponatremia in hospitalized patients, Nephrol Dial Transplant, 21, 70, 10.1093/ndt/gfi082 Musch, 2003, Fall is a frequent motif of admission in patients with chronic hyponatremia, J Am Soc Nephrol, 14, 748A Renneboog, 2003, Is asymptomatic hyponatremia a myth?, J Am Soc Nephrol, 14, 746A Arieff, 1986, Hyponatremia, convulsions, respiratory arrest, and permanent brain damage after elective surgery in healthy women, N Engl J Med, 314, 1529, 10.1056/NEJM198606123142401 Robertson, 1973, Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma, J Clin Invest, 52, 2340, 10.1172/JCI107423 Leaf, 1952, An antidiuretic mechanism not regulated by extracellular fluid tonicity, J Clin Invest, 31, 60, 10.1172/JCI102578 Weston, 1958, The pathogenesis and treatment of hyponatremia in congestive heart failure, Am J Med, 25, 558, 10.1016/0002-9343(58)90045-7 Gross, 1982, Effects of DDAVP and AVP on sodium and water balance in conscious rat, Am J Physiol, 243, R512 Verbalis, 1984, An experimental model of syndrome of inappropriate antidiuretic hormone secretion in the rat, Am J Physiol, 247, E540 Anderson, 1974, Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion, J Clin Invest, 54, 1473, 10.1172/JCI107895 Linas, 1981, Role of vasopressin in impaired water excretion in conscious rats with experimental cirrhosis, Kidney Int, 20, 173, 10.1038/ki.1981.119 Yaron, 1978, Mechanism of impaired water excretion in acute right ventricular failure in conscious dogs, Circ Res, 42, 801, 10.1161/01.RES.42.6.801 Mandell, 1980, Role of plasma arginine vasopressin in the impaired water diuresis of isolated glucocorticoid deficiency in the rat, Kidney Int, 17, 186, 10.1038/ki.1980.22 Boykin, 1979, Persistent plasma vasopressin levels in the hypoosmolar state associated with mineralocorticoid deficiency, Miner Electrolyte Metab, 2, 310 Flear, 1979, Hyponatremia and severity and outcome of myocardial infarction, Br Med J, 1, 1242, 10.1136/bmj.1.6173.1242 Bichet, 1982, Role of vasopressin in abnormal water excretion in cirrhotic patients, Ann Intern Med, 96, 413, 10.7326/0003-4819-96-4-413 Usberti, 1984, Role of plasma vasopressin in the impairment of water excretion in nephrotic syndrome, Kidney Int, 25, 422, 10.1038/ki.1984.34 Skowsky, 1978, The role of vasopressin in the impaired water excretion of myxedema, Am J Med, 64, 613, 10.1016/0002-9343(78)90581-8 Schrier, 1975, Nonosmolar factors affecting renal water excretion, N Engl J Med, 292, 81, 10.1056/NEJM197501092920207 Rossi, 1995, The mechanisms of K-opioid agonist-induced water diuresis, 289 Manning, 1985, Development of selective agonists and antagonists of vasopressin and oxytocin, 131 Burnier, 1988, Cardiovascular effects of vascular antagonists (V1) to the action of vasopressin in health and diseases, 473 Oksche, 2002, Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity, Mol Endocrinol, 16, 799, 10.1210/me.16.4.799 Adrogué, 2000, Hyponatremia, N Engl J Med, 342, 1581, 10.1056/NEJM200005253422107 Singer, 1973, Mechanisms of lithium action, N Engl J Med, 289, 254, 10.1056/NEJM197308022890508 Decaux, 1980, Treatment of the syndrome of inappropriate secretion of antidiuretic hormone by urea, Am J Med, 69, 99, 10.1016/0002-9343(80)90506-9 Hantman, 1973, Rapid correction of hyponatremia in the syndrome of inappropriate secretion of antidiuretic hormone. An alternative treatment to hypertonic saline, Ann Intern Med, 78, 870, 10.7326/0003-4819-78-6-870 Jard, 1988, Mechanisms of action of vasopressin and vasopressin antagonists, Kidney Int, 34, S38 Michell, 1979, Hormonal stimulation of phophatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin, Biochem Soc Trans, 7, 861, 10.1042/bst0070861 Thibonnier, 2001, The basic and clinical pharmacology of nonpeptide vasopressin receptor antagonists, Annu Rev Pharmacol Toxicol, 41, 175, 10.1146/annurev.pharmtox.41.1.175 Hayashi, 1994, Expression and distribution of aquaporin of collecting duct are regulated by vasopressin V2 receptor in rat kidney, J Clin Invest, 94, 1778, 10.1172/JCI117525 Innamorati, 1997, Phosphorylation of the V2 vasopressin receptor, J Biol Chem, 272, 2486, 10.1074/jbc.272.4.2486 Kojro, 1995, Ligand-induced cleavage of the V2 vasopressin receptor by a plasma membrane metalloproteinase, J Biol Chem, 270, 6476, 10.1074/jbc.270.12.6476 Sadeghi, 1995, Functional properties of mutant V 2 receptors, 445 Fujiwara, 2005, Molecular biology of hereditary diabetes insipidus, J Am Soc Nephrol, 16, 2836, 10.1681/ASN.2005040371 Yamamura, 1992, Characterization of a novel aquaretic agent, OPC 31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist, Br J Pharmacol, 105, 787, 10.1111/j.1476-5381.1992.tb09058.x Fujisawa, 1993, Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats, Kidney Int, 44, 19, 10.1038/ki.1993.207 Saito, 1995, Correction of water retention due to vasopressin excess by nonpeptide vasopressin antagonists, 635 Ohnishi, 1993, Potent aquaretic agent, J Clin Invest, 92, 2653, 10.1172/JCI116881 Chan, 1998, VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist, 439 Gross, 1999, Double blind, placebo-controlled study of the activity and tolerance of two doses of VPA-985 in patients with hyponatremia, J Am Soc Nephrol, 10, 121A Gerbes, 2003, Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist, Gastroenterology, 124, 933, 10.1053/gast.2003.50143 Tahara, 1997, Pharmacological profile of YM 087, a novel potent nonpeptide vasopressin V1a and V2 receptor antagonist, in vitro and in vivo, J Pharmacol Exp Ther, 282, 301 Risvanis, 1999, In vivo and in vitro characterisation of a nonpeptide vasopressin V1a and V2 receptor antagonist (YM 087) in the rat, Eur J Pharmacol, 381, 23, 10.1016/S0014-2999(99)00530-0 Burnier, 1997, Pharmacokinetic and pharmacodynamic effects of YM 087, a combined V1/V2 vasopressin receptor antagonist in normal subjects, Eur J Clin Pharmacol, 55, 633, 10.1007/s002280050685 Ghali, 2005, Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure, J Am Soc Nephrol, 16, 43A Serradeil-Le Gal, 1996, Characterisation of SR 121 463 A, a highly potent and selective, orally active vasopressin V2 receptor antagonist, J Clin Invest, 98, 2729, 10.1172/JCI119098 Soupart, 2004, Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion in with SR 121 463 B, an orally active, nonpeptide, vasopressin V-2 receptor antagonist, J Am Soc Nephrol, 15, 563A Yamamura, 1998, OPC-41061, a highly potent human vasopressin V2-receptor antagonist, J Pharmacol Exp Ther, 287, 860 Hirano, 2000, Effects of the V2-receptor antagonist OPC 41061 and the loop diuretic furosemide alone and in combination in rats, J Pharmacol Exp Ther, 292, 288 Monillac, 1995, The binding site of nonpeptide vasopressin V1a receptor. Evidence for a major localization within transmembrane regions, J Biol Chem, 270, 25771, 10.1074/jbc.270.43.25771 Esnouf, 1999, Further additions to MolScript version 1.4, including reading and contouring of electron-density maps, Acta Crystallogr D Biol Crytallogr, 55, 938, 10.1107/S0907444998017363 Merritt, 1994, Raster3D version 2.0. A program for photorealistic molecular graphics, Acta Crystallogr D Biol Crytallogr, 50, 869, 10.1107/S0907444994006396 Macion-Dazard, 2006, Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor, J Pharmacol Exp Ther, 316, 564, 10.1124/jpet.105.095554